Roche’s First Anti-TIGIT Data Support Dual Checkpoint Inhibition Strategy

Tiragolumab plus Tecentriq increased response rates versus Tecentriq alone in a Phase II study, with the greatest benefit in PD-L1-high NSCLC. The combination regimen already is being test in Phase III.